NPJ precision oncology
Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity.
Anna Richter, Lea Kinsky, Sandra Lange, Nares Trakooljul, Frieder Hadlich, Anett Sekora, Gudrun Knuebel, Saskia Krohn, Christian Schmidt, Michelle Busch, Tim Schreiber, Simone Kumstel, Klaus Wimmers, Hugo Murua Escobar, Christian Junghanss
Published: 202510.1038/s41698-025-01249-1
Abstract
The BCL-2 inhibitor venetoclax (VEN) has emerged as an important therapeutic backbone for hematological malignancies, but secondary resistance is a major challenge. In acute lymphoblastic leukemia (ALL), early clinical trials promise high efficacy as…
Preview only. Read the full abstract at the source